<DOC>
	<DOCNO>NCT01250223</DOCNO>
	<brief_summary>The F2-study complement previous study Follicular Lymphoma Prognostic Factors Project permit development Follicular Lymphoma International Prognostic Index ( FLIPI ) . The F2-study design prospective collection information potentially useful predict prognosis newly diagnose Follicular Lymphoma patient , purpose validate FLIPI verify whether prognostic collection data would allow development accurate prognostic index .</brief_summary>
	<brief_title>Study Prognosis Follicular Lymphoma Through Prospective Collection Data ( F2-study )</brief_title>
	<detailed_description>So far , patient lymphoma variety study aim evaluation prognosis conduct . In particular , different demographic , clinical biological factor show prognostic role univariate multivariate analysis , include age , gender , stage , tumor burden , bone marrow involvement , systemic symptom , Performance status , serum lactate dehydrogenase ( LDH ) level , anemia , erythrocyte sedimentation rate ( ESR ) beta-2 microglobulin . The combination parameter allow identification several prognostic score . Attempts define prognosis follicular lymphoma begin late '70s . Then , 1993 International Prognostic Index ( IPI ) define aggressive lymphoma also apply low-grade lymphoma lead conflict result , need prognostic index specifically design follicular lymphoma emerge . A large study prognosis patient follicular lymphoma perform Italian Lymphoma Intergroup lead definition Italian Lymphoma Intergroup ( ILI ) score , base 987 patient ( Federico M et al . Blood 2000 ; 95 ( 3 ) :783-789 ) . In 2004 Follicular Lymphoma International Prognostic Project allow definition new score 4167 pt follicular lymphoma , Follicular Lymphoma International Prognostic Index ( FLIPI ) ( Solal-CÃ©ligny P et al . Blood 2004 ; 104 ( 5 ) :1258-1265 ) . This score base evaluation age ( young 60 year vs 60 year old ) , Ann Arbor stage ( I-II v III-IV ) , number nodal site ( 0-4 v &gt; 5 ) , Hemoglobin ( Hb ) level ( great equal 12g/dL v low 12g/dL ) , serum Lactate Dehydrogenase ( LDH ) ( normal v elevate ) identifies three main group patient different survival : low risk ( 0-1 factor ) ; intermediate risk ( 2 factor ) ; high risk ( 3-5 factor ) . Notwithstanding huge number patient consider study , mention prognostic score ( IPI , ILI FLIPI ) base retrospective analysis archive data . This approach introduce bias hamper final result . A first problem selection patient influence single institution policy patient 's physician 's related factor . Furthermore , important variable , beta2-microglobulin Erythrocyte Sedimentation Rate ( ESR ) , frequently show high prognostic significance univariate analysis , hardly include final index available small number patient thus loose value multivariate analysis . Then , lack homogeneous prospectively define criterion , retrospective evaluation study parameter example clinical response easily define derived endpoint Failure Free Survival ( FFS ) Progression Free Survival ( PFS ) may bias . Finally result retrospective analysis aim evaluation survival dependent type administer treatment recent advent new drug monoclonal antibody purine analog use also elderly patient role establish prognostic factor may change . These reason think would useful start new study base prospective registration short period time patient follicular lymphoma would possible collect exhaustive set clinical data biological information .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<criteria>Patients newly diagnose follicular lymphoma Patients histologically confirm diagnosis follicular lymphoma accord WHO classification ( grade ) Age 18 Written inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Lymphoma , Follicular</keyword>
	<keyword>Prognosis</keyword>
	<keyword>Progression-Free Survival</keyword>
	<keyword>Outcome</keyword>
	<keyword>International Cooperation</keyword>
	<keyword>Data Collection</keyword>
	<keyword>Prospective study</keyword>
	<keyword>Rare Diseases</keyword>
</DOC>